🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pinghan Huang

The University of Texas Medical Branch at Galveston

ORCID: 0000-0003-2460-0695

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 3 papers. Top paper: “Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study”.

Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

Pathogens(2024)10.3390/pathogens13070539

N/A

0.165DataRank · unranked

2 citations

Pinghan Huang, Kamil Khanipov, Nathan Y. Tat, Chien-Te Kent Tseng, George Golovko +1 more

Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.07.19.549739

N/A

0DataRank · unranked

1 citations

Yichi Su, Xinzhi Zou, Pinghan Huang, Arjun Rustagi, Jaishree Garhyan +16 more

An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations

Science Translational Medicine(2024)10.1126/scitranslmed.adi0979

N/A

0DataRank · unranked

43 citations

Yichi Su, Xinzhi Zou, Pinghan Huang, Arjun Rustagi, Jaishree Garhyan +17 more